Last reviewed 2026-05-27 · How we verify

QUINGESTANOL ACETATE

Phase 2 active Small molecule

QUINGESTANOL ACETATE is a quingestanol acetate drug. It is currently in Phase 2 development for Postcoital contraception.

Quingestanol acetate works by binding to the progesterone receptor, mimicking the effects of progesterone to prevent ovulation and fertilization.

Quingestanol acetate is a small molecule drug that targets the progesterone receptor. It is classified as a quingestanol acetate and has been approved for postcoital contraception. The original developer and current owner of quingestanol acetate are unknown. Its commercial status, including patent status and generic availability, is also unknown.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	QUINGESTANOL ACETATE
Drug class	quingestanol acetate
Target	Progesterone receptor
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of it like a key fitting into a lock. Quingestanol acetate is the key that fits into the progesterone receptor lock, which is a protein on the surface of cells. When it binds, it sends a signal that prevents the release of an egg from the ovary and also prevents a fertilized egg from implanting in the uterus.

Approved indications

Postcoital contraception

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

QUINGESTANOL ACETATE CI brief — competitive landscape report
QUINGESTANOL ACETATE updates RSS · CI watch RSS

Frequently asked questions about QUINGESTANOL ACETATE

What is QUINGESTANOL ACETATE?

QUINGESTANOL ACETATE is a quingestanol acetate drug, indicated for Postcoital contraception.

How does QUINGESTANOL ACETATE work?

Quingestanol acetate works by binding to the progesterone receptor, mimicking the effects of progesterone to prevent ovulation and fertilization.

What is QUINGESTANOL ACETATE used for?

QUINGESTANOL ACETATE is indicated for Postcoital contraception.

What drug class is QUINGESTANOL ACETATE in?

QUINGESTANOL ACETATE belongs to the quingestanol acetate class. See all quingestanol acetate drugs at /class/quingestanol-acetate.

What development phase is QUINGESTANOL ACETATE in?

QUINGESTANOL ACETATE is in Phase 2.

What does QUINGESTANOL ACETATE target?

QUINGESTANOL ACETATE targets Progesterone receptor and is a quingestanol acetate.

Drug class: All quingestanol acetate drugs
Target: All drugs targeting Progesterone receptor
Therapeutic area: All drugs in Other
Indication: Drugs for Postcoital contraception

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing